<DOC>
	<DOCNO>NCT00656227</DOCNO>
	<brief_summary>This trial investigate whether four dos RN1001 ( 20ng , 50ng , 100ng 200ng ) efficacious prevent reduce resultant scar , compare placebo , apply intradermally wound margin follow excision benign naevi situate head neck .</brief_summary>
	<brief_title>A Trial Investigate Scar Improvement Efficacy RN1001 ( Avotermin ) After Head Neck Naevi Excision</brief_title>
	<detailed_description>Male female subject ( age 18-85 year ) one benign head &amp; neck naevi invite participate study . Each patient randomise particular dose group , depend number naevi suitable excision . For example , patient one excise naevi receive either dose one concentration RN1001 , placebo . A patient 2 excised naevi receive active dose , placebo . Patients 3 excised naevi receive 2 active dos , plus placebo , patient four excise naevi receive 3 active dos plus placebo . Naevi excise use punch biopsy , close standard suture . Following wound closure , study drug ( active RN1001 placebo ) administer via intradermal injection rate 100ul per linear cm wound margin . Digital film photography take pre-dose post dose ( Day 0 , day 14 , day 28 , Month 2 , 3 , 6 &amp; 12 , thereafter M24 , M36 , M48 &amp; M60 ) . Additionally , scar assessment ( complete Investigator , Research Nurse &amp; Medical photographer ) complete follow visit Day 20 onwards . Silicone mould scar take M6 , M12 annually M60 . Patients request complete questionnaire rate scar expectations/assessment total 5 occasion ( screen , Day 0 , Month 3 , Month 6 &amp; Month 12 )</detailed_description>
	<mesh_term>Nevus</mesh_term>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Weight 50 150kg body mass index within permit range height , use Quetelet 's indexweight ( kg ) /heightÂ² ( ) . The permitted index 1555 . Subjects one benign head neck naevi measure least 3cm apart . Subjects age 1885 year . Subjects examination naevus naevi , appear clinically suspicious malignancy therefore require specialist referral treatment . Subjects direct question physical examination history evidence hypertrophic keloid scar tattoo ( ) previous scar ( ) area excise . Subjects personal history bleed disorder . Subjects skin disorder chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial . Subjects clinically significant medical condition would impair wound heal include renal , hepatic , haematological , neurological immune disease . Subjects history clinically significant drug hypersensitivity lignocaine allergy surgical dressing use trial . Subjects clinically significant abnormality follow review pre trial laboratory data physical examination . Subjects take , take , investigational drug within last 30 day , long term oral , topical inhale corticosteroid therapy anti coagulant anti platelet medication . Certain drug exclude trial . These include OTC analgesic include paracetamol codeine , vitamin mineral supplement OTC cold remedy contain paracetamol active ingredient . Subjects pregnant become pregnant include Day 0 . Subjects must use suitable form contraception least first two month trial . Subjects previously positive result test HIV antibody , admit belong highrisk group . In opinion Investigator , subject likely complete trial whatever reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>